175 related articles for article (PubMed ID: 21115573)
1. Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia.
Jelassi A; Slimani A; Jguirim I; Najah M; Maatouk F; Varret M; Slimane MN
Ann Clin Biochem; 2011 Jan; 48(Pt 1):83-6. PubMed ID: 21115573
[TBL] [Abstract][Full Text] [Related]
2. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
[TBL] [Abstract][Full Text] [Related]
3. Genomic characterization of two deletions in the LDLR gene in Tunisian patients with familial hypercholesterolemia.
Jelassi A; Slimani A; Rabès JP; Jguirim I; Abifadel M; Boileau C; Najah M; M'rabet S; Mzid J; Slimane MN; Varret M
Clin Chim Acta; 2012 Dec; 414():146-51. PubMed ID: 22910581
[TBL] [Abstract][Full Text] [Related]
4. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene.
Abifadel M; Rabès JP; Jambart S; Halaby G; Gannagé-Yared MH; Sarkis A; Beaino G; Varret M; Salem N; Corbani S; Aydénian H; Junien C; Munnich A; Boileau C
Hum Mutat; 2009 Jul; 30(7):E682-91. PubMed ID: 19319977
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
[TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
[TBL] [Abstract][Full Text] [Related]
8. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
[TBL] [Abstract][Full Text] [Related]
9. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P
Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983
[TBL] [Abstract][Full Text] [Related]
10. Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.
Pisciotta L; Priore Oliva C; Cefalù AB; Noto D; Bellocchio A; Fresa R; Cantafora A; Patel D; Averna M; Tarugi P; Calandra S; Bertolini S
Atherosclerosis; 2006 Jun; 186(2):433-40. PubMed ID: 16183066
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.
Homer VM; Marais AD; Charlton F; Laurie AD; Hurndell N; Scott R; Mangili F; Sullivan DR; Barter PJ; Rye KA; George PM; Lambert G
Atherosclerosis; 2008 Feb; 196(2):659-66. PubMed ID: 17765244
[TBL] [Abstract][Full Text] [Related]
12. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
Lin J; Wang LY; Liu S; Wang XM; Yong Q; Yang Y; DU LP; Pan XD; Wang X; Jiang ZS
Chin Med J (Engl); 2010 May; 123(9):1133-8. PubMed ID: 20529551
[TBL] [Abstract][Full Text] [Related]
13. [Familial hypercholesterolemia in Tunisia].
Jelassi A; Jguirim I; Najah M; Maatouk F; Ben Hamda K; Slimane MN
Pathol Biol (Paris); 2009 Jul; 57(5):444-50. PubMed ID: 19041195
[TBL] [Abstract][Full Text] [Related]
14. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Abifadel M; Varret M; Rabès JP; Allard D; Ouguerram K; Devillers M; Cruaud C; Benjannet S; Wickham L; Erlich D; Derré A; Villéger L; Farnier M; Beucler I; Bruckert E; Chambaz J; Chanu B; Lecerf JM; Luc G; Moulin P; Weissenbach J; Prat A; Krempf M; Junien C; Seidah NG; Boileau C
Nat Genet; 2003 Jun; 34(2):154-6. PubMed ID: 12730697
[TBL] [Abstract][Full Text] [Related]
15. Limited mutational heterogeneity in the LDLR gene in familial hypercholesterolemia in Tunisia.
Jelassi A; Jguirim I; Najah M; Abid AM; Boughamoura L; Maatouk F; Rouis M; Boileau C; Rabès JP; Slimane MN; Varret M
Atherosclerosis; 2009 Apr; 203(2):449-53. PubMed ID: 18757057
[TBL] [Abstract][Full Text] [Related]
16. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.
Al-Allaf FA; Athar M; Abduljaleel Z; Taher MM; Khan W; Ba-Hammam FA; Abalkhail H; Alashwal A
Gene; 2015 Jul; 565(1):76-84. PubMed ID: 25839937
[TBL] [Abstract][Full Text] [Related]
17. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
Sjouke B; Kusters DM; Kindt I; Besseling J; Defesche JC; Sijbrands EJ; Roeters van Lennep JE; Stalenhoef AF; Wiegman A; de Graaf J; Fouchier SW; Kastelein JJ; Hovingh GK
Eur Heart J; 2015 Mar; 36(9):560-5. PubMed ID: 24585268
[TBL] [Abstract][Full Text] [Related]
18. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
[TBL] [Abstract][Full Text] [Related]
19. Molecular spectrum of autosomal dominant hypercholesterolemia in France.
Marduel M; Carrié A; Sassolas A; Devillers M; Carreau V; Di Filippo M; Erlich D; Abifadel M; Marques-Pinheiro A; Munnich A; Junien C; ; Boileau C; Varret M; Rabès JP
Hum Mutat; 2010 Nov; 31(11):E1811-24. PubMed ID: 20809525
[TBL] [Abstract][Full Text] [Related]
20. Genetic analysis of familial hypercholesterolaemia in Western Australia.
Hooper AJ; Nguyen LT; Burnett JR; Bates TR; Bell DA; Redgrave TG; Watts GF; van Bockxmeer FM
Atherosclerosis; 2012 Oct; 224(2):430-4. PubMed ID: 22883975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
